<DOC>
	<DOCNO>NCT02874937</DOCNO>
	<brief_summary>Syncope affect 50 % Canadians , cause 1-2 % emergency room visit , probably responsible CDN $ 250 million health care spending year.There know medical treatment frequent fainting . Two randomized study suggest inhibition norepinephrine transport ( NET ) reuptake sibutramine reboxetine ( NET inhibitor ) prevents syncope tilt test 80 % , investigator report sibutramine markedly reduced frequency vasovagal syncope 7 symptomatic patient . Sibutramine reboxetine , different reason , available Canada . However atomoxetine available use help patient attention deficit disorder . There data pertain hemodynamic effect patient vasovagal syncope . Although randomized clinical trial atomoxetine prevention vasovagal syncope would need clinical use , investigator first need proof principle study . The objective determine prospective , randomize , parallel , double-blind study atomoxetine 40 mg bid patient least 18 year old recurrent vasovagal syncope well prevent syncope tilt test placebo .</brief_summary>
	<brief_title>A Proof Principal Study Atomoxetine Prevention Vasovagal Syncope</brief_title>
	<detailed_description>Study Design : This randomize , double-blind , parallel-arm study subject undergo tilt table test follow 2 dos atomoxetine 40mg PO ( even morning study ) 2 dos match placebo ( separate day ) . On morning study , fast subject ( except medication ) instrument , empty bladder . ECG electrodes applied monitor continuous heart rhythm . Blood pressure monitor continuously use finger volume clamp method use one several extant device , calibrate intermittent brachial cuff measurement . One intravenous cannula place contralateral arm ( blood pressure cuff ) blood sample . Tilt Table Protocol : Following insertion venous cannulae , period least 20 minute allow elapse 10-minute basal control ( baseline ) period . Baseline data digitally record time . In last 5 minute period , blood drawn fractionate plasma catecholamine . The table rapidly raise 80 degree 60 minute . The investigator deliberately avoid tilt test method provocative medication avoid issue multiple causal factor . At 10 minute 30 minute follow onset tilt ( onset severe presyncope hypotension [ systolic blood pressure &lt; 70 mmHg ] ) , venous fractionate catecholamine sample . The study terminate subject develops hypotension severe presyncopal symptom associate systolic blood pressure ≤70 mmHg completion protocol . A sample size 56 syncope patient 85 % power detect 60 % relative risk reduction placebo outcome rate 65 % , use unmatched 2-tailed test alpha=0.05 . To compensate report dropout rate investigator inflate sample 15 % 64 subject . A formal , blind mid-way safety efficacy analysis perform p &lt; 0.05 stop rule efficacy . This also provide 85 % power detect 80 % relative risk reduction . Randomization carry use computerized algorithm . Patients randomize double blind fashion receive atomoxetine 40mg PO x2 match placebo 1:1 randomization ratio . Medication container centrally fill labeled randomization code number .</detailed_description>
	<mesh_term>Syncope</mesh_term>
	<mesh_term>Syncope , Vasovagal</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>≥1 syncopal spell year precede enrolment ≥2 point Calgary Syncope Symptom Score Age ≥18 year inform consent The Calgary Syncope Symptom Score use diagnose VVS patient structurally normal heart Other cause syncope , ventricular tachycardia , complete heart block , orthostatic hypotension hypersensitive carotid sinus syndrome An inability give inform consent Important valvular , coronary , myocardial conduction abnormality significant arrhythmia Hypertrophic cardiomyopathy Permanent pacemaker Seizure disorder Hypertension define &gt; 150/90 mm Hg Pregnancy Glaucoma Medications know effect blood pressure Known hypersensitivity atomoxetine derivatives Other factor , investigator 's opinion , would prevent subject complete protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Syncope</keyword>
	<keyword>Vasovagal</keyword>
	<keyword>Atomoxetine</keyword>
</DOC>